Search

Introduction: The potential for deployment of Artificial Intelligence (AI) technologies in various fields of medicine is vast, yet acceptance of AI amongst clinicians has been patchy. This research therefore examines the role of antecedents, namely trust, attitude, and beliefs in driving AI acceptance in clinical practice., Methods: We utilized online surveys to gather data from clinicians in the field of gastroenterology., Results: A total of 164 participants responded to the survey. Participants had a mean age of 44.49 (SD = 9.65). Most participants were male ( n  = 116, 70.30%) and specialized in gastroenterology ( n  = 153, 92.73%). Based on the results collected, we proposed and tested a model of AI acceptance in medical practice. Our findings showed that while the proposed drivers had a positive impact on AI tools' acceptance, not all effects were direct. Trust and belief were found to fully mediate the effects of attitude on AI acceptance by clinicians., Discussion: The role of trust and beliefs as primary mediators of the acceptance of AI in medical practice suggest that these should be areas of focus in AI education, engagement and training. This has implications for how AI systems can gain greater clinician acceptance to engender greater trust and adoption amongst public health systems and professional networks which in turn would impact how populations interface with AI. Implications for policy and practice, as well as future research in this nascent field, are discussed., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Schulz, Lwin, Kee, Goh, Lam and Sung.)

The robustness of a breast cancer gene signature, the super-proliferation set (SPS), is initially tested and investigated on breast cancer cell lines from the Cancer Cell Line Encyclopaedia (CCLE). Previously, SPS was derived via a meta-analysis of 47 independent breast cancer gene signatures, benchmarked on survival information from clinical data in the NKI dataset. Here, relying on the stability of cell line data and associative prior knowledge, we first demonstrate through Principal Component Analysis (PCA) that SPS prioritizes survival information over secondary subtype information, surpassing both PAM50 and Boruta, an artificial intelligence-based feature-selection algorithm, in this regard. We can also extract higher resolution 'progression' information using SPS, dividing survival outcomes into several clinically relevant stages ('good', 'intermediate', and 'bad) based on different quadrants of the PCA scatterplot. Furthermore, by transferring these 'progression' annotations onto independent clinical datasets, we demonstrate the generalisability of our method on actual patient data. Finally, via the characteristic genetic profiles of each quadrant/stage, we identified efficacious drugs using their gene reversal scores that can shift signatures across quadrants/stages, in a process known as gene signature reversal. This confirms the power of meta-analytical approaches for gene signature inference in breast cancer, as well as the clinical benefit in translating these inferences onto real-world patient data for more targeted therapies., Competing Interests: Conflict of interest The authors declare no conflicting interests, financial or otherwise., (Copyright © 2023 Elsevier Ltd. All rights reserved.)

Sentiment Analysis (SA) is a category of data mining techniques that extract latent representations of affective states within textual corpuses. This has wide ranging applications from online reviews to capturing mental states. In this paper, we present a novel SA feature set; Emotional Variance Analysis (EVA), which captures patterns of emotional instability. Applying EVA on student journals garnered from an Experiential Learning (EL) course, we find that EVA is useful for profiling variations in sentiment polarity and intensity, which in turn can predict academic performance. As a feature set, EVA is compatible with a wide variety of Artificial Intelligence (AI) and Machine Learning (ML) applications. Although evaluated on education data, we foresee EVA to be useful in mental health profiling and consumer behaviour applications. EVA is available at https://qr.page/g/5jQ8DQmWQT4. Our results show that EVA was able to achieve an overall accuracy of 88.7% and outperform NLP (76.0%) and SentimentR (58.0%) features by 15.8% and 51.7% respectively when predicting student experiential learning grade scores through a Multi-Layer Perceptron (MLP) ML model., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Tan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Batch effects (BEs) are technical biases that may confound analysis of high-throughput biotechnological data. BEs are complex and effective mitigation is highly context-dependent. In particular, the advent of high-resolution technologies such as single-cell RNA sequencing presents new challenges. We first cover how BE modeling differs between traditional datasets and the new data landscape. We also discuss new approaches for measuring and mitigating BEs, including whether a BE is significant enough to warrant correction. Even with the advent of machine learning and artificial intelligence, the increased complexity of next-generation biotechnological data means increased complexities in BE management. We forecast that BEs will not only remain relevant in the age of big data but will become even more important., Competing Interests: Declaration of interests The authors declare no conflicting interest, financial or otherwise., (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Natural products (NPs) constitute a large reserve of bioactive compounds useful for drug development. Recent advances in high-throughput technologies facilitate functional analysis of therapeutic effects and NP-based drug discovery. However, the large amount of generated data is complex and difficult to analyze effectively. This limitation is increasingly surmounted by artificial intelligence (AI) techniques but more needs to be done. Here, we present and discuss two crucial issues limiting NP-AI drug discovery: the first is on knowledge and resource development (data integration) to bridge the gap between NPs and functional or therapeutic effects. The second issue is on NP-AI modeling considerations, limitations and challenges., Competing Interests: Conflicts of interest The authors declare no competing interests, financial or otherwise., (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Artificial intelligence (AI) is profoundly changing biotechnological innovation. Beyond direct application, it is also a useful tool for adaptive learning and forging new conceptual connections within the vast network of knowledge for the advancement of biotechnology. Here, we discuss a new paradigm for biotechnology education that involves coevolution with AI., (Copyright © 2018 Elsevier Ltd. All rights reserved.)